Primary Surgery, Concurrent Chemoradiation in Head & Neck Cancer Provide Similar Outcomes
the Cancer Therapy Advisor take:
Patients with advanced, non-metastatic head and neck squamous cell carcinoma experience similar outcomes when treated with either primary surgery or concurrent chemotherapy and radiotherapy (CRRT), according to a recent study published in Cancer.
However, patients with cancers of the oral cavity or maxillary sinus should consider primary surgery as the main treatment modality.
Narayanan Gopalakrishna Iyer, PhD, MBBS, and colleagues at the National Cancer Centre in Singapore examined 119 patients with stage ¾ resectable head and neck squamous cell carcinoma, with 60 who had undergone primary surgery and 59 who were adminstered CRRT. Median follow-up for surviving patients was 13 years.
They found no statistically significant difference in overall survival or disease-specific survival in either group when analyzing the entire cohort.
For patients with cancer of the oral cavity or maxillary sinus, however, survival was significantly better in those who had undergone primary surgery.
“These long-term results demonstrate a significant advantage for primary surgery in patients with cancers of the oral cavity or maxillary sinus,” the authors concluded.
Head and neck squamous cancer patients experience similar outcomes when treated with either primary surgery or CRRT.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Plastics and Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer